The Solution 
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
Call for Science
For the first time, egnite is launching an open call for research ideas through an Investigator-Initiated Study (IIS) grant. We are inviting U.S.-based researchers to submit original study proposals, with the selected proposal receiving ten hours of dedicated data science support. The egnite team will conduct analyses using the egnite Registry, with the goal of submitting findings to a major cardiovascular conference.
See egnite’s most recent TCT-featured publication in JACC, led by Dr. Philippe Généreux.
The Mortality Burden of Untreated Aortic Stenosis
Authors: Philippe Généreux, Rahul P. Sharma, Robert J. Cubeddu, Lucy Aaron, Omar M. Abdelfattah, Konstantinos P. Koulogiannis, Leo Marcoff, Mostafa Naguib, Samir R. Kapadia, Rajendra R. Makkar, Vinod H. Thourani, Benjamin S. van Boxtel, David J. Cohen, Michael Dobbles, Glenn R. Barnhart, Michelle Kwon, Philippe Pibarot, Martin B. Leon, and Linda D. Gillam
Curious about the data fields available for your research? Our real-world clinical data represents:
- 13.7M+ Patients
- 45+ Health Systems
- 800+ Facilities
Tell us About Your Research
The Process
egnite will select one research proposal through its Investigator-Initiated Study (IIS) grant, contributing data science expertise to support the investigator-led research.
Proposals focused on descriptive analytics and survival trends will be prioritized.
How To Submit
To be considered, please complete the form on the right. The form can only be submitted once all required fields are completed. See examples below for reference:
- The Clinical Question: What do you want to know and why does it matter?
- Primary Hypothesis (consider the PICO framework):
- Example: "Among patients with HFpEF, use of SGLT2 inhibitors—compared with non-use—was associated with lower readmission rates over a 12-month period."
- Significance and Potential to Impact the Field: What would be the clinical implications if your hypothesis proves to be true?
SUBMISSION DEADLINE: March 31, 2026
We look forward to hearing your ideas and potentially partnering with you on this research! If you have further questions about the research dataset available, please reach out to Mike Dobbles, egnite's Chief Data Officer, at michael.dobbles@egnitehealth.com.
- Example: "Among patients with HFpEF, use of SGLT2 inhibitors—compared with non-use—was associated with lower readmission rates over a 12-month period."
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.